RhumbLine Advisers’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.5M | Buy |
107,385
+2,826
| +3% | +$39.5K | ﹤0.01% | 2039 |
|
|
2025
Q1 | $1.41M | Buy |
104,559
+4,621
| +5% | +$62.3K | ﹤0.01% | 1998 |
|
|
2024
Q4 | $1.92M | Buy |
99,938
+11,594
| +13% | +$222K | ﹤0.01% | 1899 |
|
|
2024
Q3 | $2.01M | Sell |
88,344
-2,482
| -3% | -$56.5K | ﹤0.01% | 1910 |
|
|
2024
Q2 | $1.18M | Buy |
90,826
+23,305
| +35% | +$303K | ﹤0.01% | 2152 |
|
|
2024
Q1 | $1.18M | Buy |
67,521
+7,087
| +12% | +$124K | ﹤0.01% | 2163 |
|
|
2023
Q4 | $1.32M | Sell |
60,434
-63
| -0.1% | -$1.37K | ﹤0.01% | 2124 |
|
|
2023
Q3 | $928K | Buy |
60,497
+1,015
| +2% | +$15.6K | ﹤0.01% | 2252 |
|
|
2023
Q2 | $1.42M | Buy |
59,482
+6,514
| +12% | +$155K | ﹤0.01% | 2105 |
|
|
2023
Q1 | $1.35M | Buy |
52,968
+5,715
| +12% | +$145K | ﹤0.01% | 2005 |
|
|
2022
Q4 | $1.38M | Buy |
47,253
+12,390
| +36% | +$362K | ﹤0.01% | 1979 |
|
|
2022
Q3 | $715K | Buy |
34,863
+3,150
| +10% | +$64.6K | ﹤0.01% | 2328 |
|
|
2022
Q2 | $367K | Buy |
+31,713
| New | +$367K | ﹤0.01% | 2647 |
|
|
2019
Q2 | – | Sell |
-2,184
| Closed | -$91K | – | 3006 |
|
|
2019
Q1 | $91K | Sell |
2,184
-39
| -2% | -$1.63K | ﹤0.01% | 2870 |
|
|
2018
Q4 | $101K | Buy |
2,223
+754
| +51% | +$34.3K | ﹤0.01% | 2882 |
|
|
2018
Q3 | $123K | Sell |
1,469
-54
| -4% | -$4.52K | ﹤0.01% | 2839 |
|
|
2018
Q2 | $146K | Buy |
1,523
+667
| +78% | +$63.9K | ﹤0.01% | 2814 |
|
|
2018
Q1 | $90K | Buy |
856
+180
| +27% | +$18.9K | ﹤0.01% | 2756 |
|
|
2017
Q4 | $106K | Sell |
676
-153
| -18% | -$24K | ﹤0.01% | 2766 |
|
|
2017
Q3 | $114K | Buy |
829
+24
| +3% | +$3.3K | ﹤0.01% | 2853 |
|
|
2017
Q2 | $156K | Buy |
+805
| New | +$156K | ﹤0.01% | 2827 |
|